Daraxonrasib Nearly Doubles Pancreatic Cancer Survival Rates as Italian Patients Face Access Hurdles
Daraxonrasib, a targeted oral therapy, nearly doubles median survival rates for metastatic pancreatic cancer patients compared to standard chemotherapy, according to clinical trial data presented at the American Society of Clinical Oncology (ASCO) plenary session and reported by RaiNews. The experimental drug achieved a median survival of 13.2 months, compared to 6.7 months with chemotherapy, among 500 patients with previously treated metastatic disease.
Clinical Trial Results from the RASolute Studies
The international RASolute 302 trial evaluated 500 patients with previously treated metastatic pancreatic adenocarcinoma, demonstrating that daraxonrasib extended median overall survival to 13.2 months versus 6.7 months for chemotherapy, as detailed by Mondosanità with findings published in the New England Journal of Medicine. At twelve months, 53.2% of patients receiving the new drug were alive, compared to 17.3% in the chemotherapy control group. The therapy is administered in tablet form and presents fewer side effects than traditional chemotherapy regimens.
Additional clinical trials are currently underway at Rome’s Policlinico Gemelli hospital, as reported by Vanity Fair Italia. These include the RASolute 303 trial evaluating first-line metastatic disease and a separate trial in the adjuvant setting for patients who have undergone pancreatic surgery. A third trial combining daraxonrasib with a second KRAS-targeted inhibitor is scheduled to begin shortly.
Regulatory Approvals and European Union Delays
The United States Food and Drug Administration (FDA) approved daraxonrasib on August 26, 2026, making the drug commercially available to American patients who have exhausted initial treatment options, according to Mondosanità. In contrast, the European Medicines Agency (EMA) is still reviewing the drug dossier through an accelerated procedure, leaving patients in Italy and other EU nations without ordinary access through national health services.
France has already raised the issue at a parliamentary level, with a formal inquiry submitted to the French Senate asking the government to detail compassionate access requests for the drug, as noted by Mondosanità. Meanwhile, Italian oncology organizations have pressed for immediate intervention to secure supplies for local patients ahead of the formal European regulatory timeline.
Italian Access Debates and Compassionate Use Negotiations
The Italian Association of Medical Oncology (AIOM) recently called on manufacturer Revolution Medicines to provide free access to daraxonrasib for Italian patients through a compassionate use program while waiting for European clearance, according to RaiNews. AIOM president Massimo Di Maio noted that while the drug significantly extends life, it represents a life-prolonging treatment rather than a cure.
In response to the association’s appeal, Italian Undersecretary of Health Marcello Gemmato announced that the Italian Medicines Agency (AIFA) has opened discussions with Revolution Medicines to establish a national compassionate use program. Currently, Italian patients can only receive daraxonrasib through authorized clinical trials, such as the RASolute 302, 303, and 304 protocols, provided they meet strict eligibility criteria.
Patient Journeys and Treatment Costs Abroad
High costs and delayed regulatory approvals have driven some European patients to seek treatment directly in the United States. Radio host Max Parisi traveled to the U.S. after exhausting standard options in Italy, paying approximately 36/37 mila euro for a single month’s supply of daraxonrasib, funded largely through a public crowdfunding campaign, as reported by Il Fatto Quotidiano and Vanity Fair Italia. Parisi experienced a liver crisis shortly after arriving in the U.S. but reported rapid clinical improvement after taking his first doses of the medication, with treating physicians observing significant recovery in liver function.
Frequently Asked Questions
When was daraxonrasib approved by the FDA?
The FDA officially approved daraxonrasib on August 26, 2026, making it available to patients in the United States who have completed prior therapies.
What survival gains did the RASolute 302 trial record?
The RASolute 302 trial recorded a median overall survival of 13.2 months for patients treated with daraxonrasib, compared to 6.7 months for those receiving standard chemotherapy.
How can Italian patients currently access the drug?
Italian patients can access daraxonrasib exclusively through authorized clinical trials, including the RASolute 302, 303, and 304 protocols at participating centers like Policlinico Gemelli in Rome, while AIFA negotiates a potential compassionate use program with manufacturer Revolution Medicines.
Worth a look